Glycogen synthase kinase 3 inhibitors induce the canonical WNT/[Beta]-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma

Embryonal rhabdomyosarcoma (ERMS) is a common pediatric malignancy of muscle, with relapse being the major clinical challenge. Self-renewing tumor-propagating cells (TPCs) drive cancer relapse and are confined to a molecularly definable subset of ERMS cells. To identify drugs that suppress ERMS self...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 111; no. 14; p. 5349
Main Authors Chen, Eleanor Y, DeRan, Michael T, Ignatius, Myron S, Grandinetti, Kathryn Brooke, Clagg, Ryan, McCarthy, Karin M, Lobbardi, Riadh M, Brockmann, Jillian, Keller, Charles, Wu, Xu, Langenau, David M
Format Journal Article
LanguageEnglish
Published Washington National Academy of Sciences 08.04.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Embryonal rhabdomyosarcoma (ERMS) is a common pediatric malignancy of muscle, with relapse being the major clinical challenge. Self-renewing tumor-propagating cells (TPCs) drive cancer relapse and are confined to a molecularly definable subset of ERMS cells. To identify drugs that suppress ERMS self-renewal and induce differentiation of TPCs, a large-scale chemical screen was completed. Glycogen synthase kinase 3 (GSK3) inhibitors were identified as potent suppressors of ERMS growth through inhibiting proliferation and inducing terminal differentiation of TPCs into myosin-expressing cells. In support of GSK3 inhibitors functioning through activation of the canonical WNT/β-catenin pathway, recombinant WNT3A and stabilized β-catenin also enhanced terminal differentiation of human ERMS cells. Treatment of ERMS-bearing zebrafish with GSK3 inhibitors activated the WNT/β-catenin pathway, resulting in suppressed ERMS growth, depleted TPCs, and diminished self-renewal capacity in vivo. Activation of the canonical WNT/β-catenin pathway also significantly reduced self-renewal of human ERMS, indicating a conserved function for this pathway in modulating ERMS self-renewal. In total, we have identified an unconventional tumor suppressive role for the canonical WNT/β-catenin pathway in regulating self-renewal of ERMS and revealed therapeutic strategies to target differentiation of TPCs in ERMS. [PUBLICATION ABSTRACT]
ISSN:0027-8424
1091-6490